ICER casts doubt on cost-effectiveness of newer MM drugs

In a draft evidence Kyprolis carfilzomib, Empliciti elotuzumab and Ninlaro ixazomib, all in combination with Revlimid lenalidomide and dexamethasone, "provide an incremental or better net health benefit for both second-line and third-line

Read the full 327 word article

User Sign In